Clinical trial
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332 is registered in ClinicalTrials.gov with Inhibikase Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Inhibikase Therapeutics
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- April 23, 2026
- Completion date
- December 31, 2029
- Enrollment
- 486 (estimated)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.